Bupropion in the Treatment of Pathological Gambling

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Iowa
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Bupropion

Criteria

Inclusion Criteria:

• Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);

• Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS);

• Receive a score of 5 or more on the South Oaks Gambling Screen (SOGS);

• Have PG for at least one year;

• Have had at least 2 or more gambling episodes during the 2-week screening period;

• Speak standard English;

• Be able to give written informed consent.

Exclusion Criteria:

• Evidence of current (past 3 months) substance misuse;

• Had a Hamilton Depression Rating Scale (HDRS)27 score of 18 or more (or a score on item 1 of greater than 2;

• Had a current eating disorder (except binge eating disorder);

• Had any history of seizures, or suicidal or aggressive behavior;

• Had a urine drug screen positive for stimulants, opiates, hallucinogens, or phencyclidine;

• Had a current or past psychotic disorder, bipolar disorder, or significant cognitive disorder;

• Received monoamine oxidase inhibitors within 3 weeks of randomization, long acting phenothiazine within 3 months of randomization,fluoxetine within 4 weeks of randomization, or other psychotropic drugs within 2 weeks of randomization;

• Had prior exposure to bupropion;

• Were engaged in individual, group, or couples psychotherapy during the 2 weeks before randomization, (except Gamblers Anonymous).